Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Autolus Therapeutics plc (AUTL)

2.41   0.09 (3.88%) 09-28 16:00
Open: 2.395 Pre. Close: 2.32
High: 2.4144 Low: 2.29
Volume: 186,213 Market Cap: 419(M)

Technical analysis

as of: 2023-09-28 4:49:03 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 3.45     One year: 3.98
Support: Support1: 2.23    Support2: 1.85
Resistance: Resistance1: 2.96    Resistance2: 3.41
Pivot: 2.7
Moving Average: MA(5): 2.35     MA(20): 2.81
MA(100): 2.8     MA(250): 2.42
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 13.2     %D(3): 11.5
RSI: RSI(14): 31.9
52-week: High: 3.53  Low: 1.6
Average Vol(K): 3-Month: 403 (K)  10-Days: 302 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AUTL ] has closed above bottom band by 22.3%. Bollinger Bands are 32.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.42 - 2.43 2.43 - 2.44
Low: 2.26 - 2.27 2.27 - 2.29
Close: 2.38 - 2.41 2.41 - 2.43

Company Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Headline News

Sun, 17 Sep 2023
Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update - MarketBeat

Tue, 05 Sep 2023
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood - Yahoo Finance

Mon, 07 Aug 2023
Autolus Therapeutics plc (NASDAQ:AUTL) Q2 2023 Earnings Call Transcript - Yahoo Finance

Wed, 19 Jul 2023
Autolus Therapeutics announces appointment of Robert F. Dolski as ... - GlobeNewswire

Fri, 16 Jun 2023
Autolus Therapeutics Presents Positive Results from AUTO4 in ... - GlobeNewswire

Fri, 02 Jun 2023
Is Autolus Therapeutics PLC (AUTL) a Good Choice in Biotechnology Friday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 174 (M)
% Held by Insiders 5.622e+007 (%)
% Held by Institutions 8.4 (%)
Shares Short 1,870 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.5968e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 223.6
Return on Equity (ttm) -27.3
Qtrly Rev. Growth 7.49e+006
Gross Profit (p.s.) 0
Sales Per Share -47.22
EBITDA (p.s.) -8.84189e+007
Qtrly Earnings Growth -1.2
Operating Cash Flow 0 (M)
Levered Free Cash Flow -127 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 2.7

Stock Dividends

Dividend 0
Forward Dividend 1.37e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.